Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Thrombotic risk correlates with mutational status in true essential thrombocythemia.

Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi ML.

Eur J Clin Invest. 2016 Aug;46(8):683-9. doi: 10.1111/eci.12647. Epub 2016 Jul 6.

PMID:
27271054
2.

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.

Sun C, Zhou X, Zou ZJ, Guo HF, Li JY, Qiao C.

Chin Med J (Engl). 2016 Aug 5;129(15):1778-83. doi: 10.4103/0366-6999.186641.

3.

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.

Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Am J Hematol. 2016 May;91(5):503-6. doi: 10.1002/ajh.24338. Epub 2016 Apr 4.

4.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.

Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

5.

Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.

Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH.

Ann Hematol. 2014 Dec;93(12):2029-36.

PMID:
25015052
6.

JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.

Wang J, Zhang B, Chen B, Zhou RF, Zhang QG, Li J, Yang YG, Zhou M, Shao XY, Xu Y, Xu XH, Ouyang J, Xu J, Ye Q.

Hematology. 2017 Apr;22(3):145-148. doi: 10.1080/10245332.2016.1252003. Epub 2016 Nov 22.

PMID:
27875935
7.

JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.

Pósfai É, Marton I, Király PA, Kotosz B, Kiss-László Z, Széll M, Borbényi Z.

Pathol Oncol Res. 2015 Jul;21(3):751-8. doi: 10.1007/s12253-014-9885-4. Epub 2015 Jan 10.

PMID:
25573593
8.

Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes.

Alvarez-Larran A, Martínez D, Arenillas L, Rubio A, Arellano-Rodrigo E, Hernández Boluda JC, Papaleo N, Caballero G, Martínez C, Ferrer-Marín F, Mata MI, Pérez-Encinas M, Durán MA, Alonso JM, Carreño-Tarragona G, Alonso JM, Noya S, Magro E, Pérez R, López-Guerra M, Pastor-Galán I, Cervantes F, Besses C, Colomo L, Rozman M.

J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.

PMID:
29934356
9.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

10.

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.

Kim BH, Cho YU, Bae MH, Jang S, Seo EJ, Chi HS, Choi Y, Kim DY, Lee JH, Lee JH, Lee KH, Park YM, Lee JK, Park CJ.

J Korean Med Sci. 2015 Jul;30(7):882-8. doi: 10.3346/jkms.2015.30.7.882. Epub 2015 Jun 10.

11.

Anagrelide and Mutational Status in Essential Thrombocythemia.

Iurlo A, Cattaneo D, Orofino N, Bucelli C, Fabris S, Cortelezzi A.

BioDrugs. 2016 Jun;30(3):219-23. doi: 10.1007/s40259-016-0170-9.

PMID:
27041108
12.

Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.

Gangat N, Wassie EA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Passamonti F, Tefferi A.

Eur J Haematol. 2015 Jan;94(1):31-6. doi: 10.1111/ejh.12389. Epub 2014 Dec 4.

PMID:
24889737
13.

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A, Barbui T.

Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.

14.

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.

Int J Hematol. 2018 Jun;107(6):673-680. doi: 10.1007/s12185-018-2421-7. Epub 2018 Feb 20.

PMID:
29464483
16.

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Guo H, Chen X, Tian R, Chang J, Li J, Tan Y, Xu Z, Ren F, Zhao J, Pan J, Zhang N, Wang X, He J, Yang W, Wang H.

PLoS One. 2015 Sep 16;10(9):e0138250. doi: 10.1371/journal.pone.0138250. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0141173.

17.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

18.

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].

Ben Said M, Gandrille S, Fischer AM, Darnige L.

Pathol Biol (Paris). 2015 Jun;63(3):117-21. doi: 10.1016/j.patbio.2015.01.001. Epub 2015 Apr 1. Review. French.

PMID:
25840625
19.

CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.

Ojeda MJ, Bragós IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF.

Hematology. 2018 May;23(4):208-211. doi: 10.1080/10245332.2017.1385891. Epub 2017 Oct 9.

PMID:
28990497
20.

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.

Mela Osorio MJ, Ferrari L, Goette NP, Gutierrez MI, Glembotsky AC, Maldonado AC, Lev PR, Alvarez C, Korin L, Marta RF, Molinas FC, Heller PG.

Eur J Haematol. 2016 Apr;96(4):435-42. doi: 10.1111/ejh.12614. Epub 2015 Jul 19.

PMID:
26119186

Supplemental Content

Support Center